Skip to main content

Advertisement

Log in

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hotta K, Matsuo K, Ueoka H et al (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852–3859

    Article  CAS  PubMed  Google Scholar 

  2. Hotta K, Matsuo K, Ueoka H et al (2004) Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15:1782–1789

    Article  CAS  PubMed  Google Scholar 

  3. Hotta K, Matsuo K (2007) Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2:96

    Article  PubMed  Google Scholar 

  4. Hotta K, Fujiwara Y, Matsuo K et al (2007) Recent improvement in the survival of patients with advanced non small cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 109:939–948

    Article  CAS  PubMed  Google Scholar 

  5. Hotta K, Takigawa N, Hisamoto-Sato A et al (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43:1115–1123

    Article  PubMed  Google Scholar 

  6. Ninomiya K, Hotta K, Hisamoto-Sato A et al (2016) Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 21:81–87

    Article  CAS  PubMed  Google Scholar 

  7. Hotta K, Ninomiya K, Takigawa N et al (2015) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol 45:603–604

    PubMed  Google Scholar 

  8. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  PubMed  Google Scholar 

  9. Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hotta K, Kiura K, Toyooka S et al (2007) Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer. J Thorac Oncol 2:632–637

    Article  PubMed  Google Scholar 

  11. Mok TS, Wu Y-L, Ahn M-J et al (2017) AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640

    Article  CAS  PubMed  Google Scholar 

  12. Jänne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689–1699

    Article  PubMed  Google Scholar 

  13. Hata A, Katakami N, Yoshioka H et al (2015) Spatiotemporal T790M Heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 10:1553–1559

    Article  CAS  PubMed  Google Scholar 

  14. Ichihara E, Hotta K, Kubo T et al (2018) Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget 9(50):29525–29531

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hata A, Masago K, Katakami N et al (2014) Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 9:e64–e65

    Article  PubMed  Google Scholar 

  16. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T et al (2018) FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125

    Article  CAS  PubMed  Google Scholar 

  17. National Comprehensive Cancer Network homepage. https://www.nccn.org/. Accessed 5 May 2018

  18. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30

    Article  PubMed  Google Scholar 

  19. Tokaca N, Wotherspoon A, Nicholson AG et al (2017) Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung Cancer 111:65–68

    Article  PubMed  Google Scholar 

  20. Peters S, Camidge DR, Shaw AT et al (2017) ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838

    Article  CAS  PubMed  Google Scholar 

  21. Hida T, Nokihara H, Kondo M et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29–39

    Article  CAS  PubMed  Google Scholar 

  22. Horinouchi H, Maemondo M, Hida T et al (2017) Phase 2 study of ceritinib in patients with ALK + NSCLC with prior alectinib treatment in Japan: ASCEND-9. J Thorac Oncol 12(Supple 2):S1952–S1953

    Article  Google Scholar 

  23. Isozaki H, Hotta K, Ichihara E et al (2016) Protocol design for the bench to bed trial in alectinib-refractory non-small-cell lung cancer patients harboring the EML4-ALK fusion gene (ALRIGHT/OLCSG1405). Clin Lung Cancer 17:602–605

    Article  CAS  PubMed  Google Scholar 

  24. Gainor JF, Dardaei L, Yoda S et al (2016) Molecular mechanisms of resistance to first- and second-Generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118–1133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833

    Article  CAS  PubMed  Google Scholar 

  26. Sheng J, Fang W, Yu J et al (2016) Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep 6:20090

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Song Z, Yu X, Zhang Y (2016) Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Lung Cancer 99:166–171

    Article  PubMed  Google Scholar 

  28. Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265

    Article  PubMed  Google Scholar 

  29. Gadgeel S, Kowanetz F, Zou W et al Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L + NSCLC: Results from the randomized OAK study. ESMO 2017 (Abs 1296O)

  30. Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

    Article  CAS  PubMed  Google Scholar 

  31. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092

    Article  CAS  PubMed  Google Scholar 

  32. Kato Y, Hotta K, Takigawa N et al (2014) Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 73:943–950

    Article  CAS  PubMed  Google Scholar 

  33. Hotta K, Kiura K, Tabata M et al (2014) A Survey of Japanese thoracic oncologists’perception of diagnostic and treatment strategies for EGFR-mutant or EML4-ALK-fusion non-small cell lung cancer. Chest 146:e222–e225

    Article  PubMed  Google Scholar 

  34. Hotta K, Tabata M, Kiura K et al (2007) Gefitinib induces premature senescence in non-small-cell lung cancer cells with or without EGFR gene mutation. Oncol Rep 17:313–317

    CAS  PubMed  Google Scholar 

  35. Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585–4593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kim TJ, Hong SA, Kim O et al (2017) Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget 8:107630–107639

    PubMed  PubMed Central  Google Scholar 

  37. Kowanetz M, Socinski MA, Zou W et al (2018) IMpower150: Efficacy of atezolizumab plus bevacizumab and chemotherapy in 1L metastatic nonsquamous NSCLC across key subgroups. Presented at: 2018 AACR Annual Meeting, 2018; Chicago, Illinois. Abstract CT076

  38. Haratani K, Hayashi H, Tanaka T et al (2017) Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 28:1532–1539

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

KH has received honoraria outside the current work from AstraZeneca, Ono Pharmaceutical, Astellas, Novartis, BMS, MSD, Eli Lilly Japan, Daiichi-Sankyo Pharmaceutical, Boehringer-Ingelheim, Nihon Kayaku, Taiho Pharmaceutical, and Chugai Pharmaceutical. KH has also received research funding outside the current work from AstraZeneca, Boehringer-Ingelheim, Ono Pharmaceutical, Astellas, Novartis, BMS, Eli Lilly Japan, MSD, and Chugai Pharmaceutical. KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Sanofi-Aventis.

Author information

Authors and Affiliations

Authors

Contributions

KH and others: collection, assembly, analysis, and interpretation of data. Drafting of the manuscript and critically reviewing or revising the manuscript for important intellectual content. All authors have approved the final version of the manuscript.

Corresponding author

Correspondence to Katsuyuki Hotta.

Ethics declarations

Conflict of interest

No other authors declare any conflicts of interest regarding this study.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hotta, K., Ninomiya, K., Ichihara, E. et al. Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. Int J Clin Oncol 24, 41–45 (2019). https://doi.org/10.1007/s10147-018-1344-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1344-x

Keywords

Navigation